Preview

Андрология и генитальная хирургия

Расширенный поиск

Влияние тестостерона на пуриновый обмен и подагру

https://doi.org/10.17650/1726-9784-2021-22-3-11-17

Полный текст:

Аннотация

В регуляции пуринового обмена участвует множество различных факторов. Немаловажную роль играет уровень половых гормонов: высокие концентрации андрогенов приводят к более высокому, а эстрогенов – к относительно низкому уровню мочевой кислоты. Однако, по результатам многочисленных исследований, показано, что влияние половых гормонов не ограничивается только концентрацией мочевой кислоты. Половые гормоны оказывают влияние на воспалительные процессы в организме, модулируя выработку провоспалительных цитокинов и регулируя соответствующие сигнальные пути. Дефицит андрогенов может приводить к развитию ожирения и метаболических нарушений, что может вносить вклад в развитие и течение подагры. В данном обзоре рассмотрено влияние тестостерона, а также изменений его концентрации на динамику пуринового обмена и подагру.

Об авторе

Т. С. Паневин
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГКУ «Консультативно-диагностический центр Генерального штаба Вооруженных сил Российской Федерации»
Россия

Тарас Сергеевич Паневин

115522 Москва, Каширское шоссе, 34А
119019 Москва, пер. Колымажный, 7, стр. 4



Список литературы

1. de Oliveira E.P., Burini R.C. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 2012;4:12. DOI: 10.1186/1758-5996-4-12.

2. Doghramji P.P., Wortmann R.L. Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med 2012;124(6):98–109. DOI: 10.3810/pgm.2012.11.2616.

3. Garbagnati E., Boschetti M. Uric acid homeostasis in lean and obese girls during pubertal development. Metabolism 1994;43(7):819–21. DOI: 10.1016/0026-0495(94)90260-7.

4. Garbagnati E. Urate changes in lean and obese boys during pubertal development. Metabolism 1996;45(2):203–5. DOI: 10.1016/s0026-0495(96)90054-2.

5. Wabitsch M., Hauner H., Heinze E. et al. Body-fat distribution and changes in the atherogenic risk-factor profile in obese adolescent girls during weight reduction. Am J Clin Nutr 1994;60(1):54–60. DOI: 10.1093/ajcn/60.1.54.

6. Stamp L.K., Wells J.E., Pitama S. et al. Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities. Intern Med J 2013;43(6):678–84. DOI: 10.1111/imj.12062.

7. Denzer C., Muche R., Mayer H. et al. Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab 2003;16(9):1225–32. DOI: 10.1515/jpem.2003.16.9.1225.

8. Liegibel U.M., Sommer U., Boercsoek I. et al. Androgen receptor isoforms AR-A and AR-B display functional differences in cultured human bone cells and genital skin fibroblasts. Steroids 2003;68(14):1179–87. DOI: 10.1016/j.steroids.2003.08.016.

9. Lindzey J., Kumar M.V., Grossman M. et al. Molecular Mechanisms of Androgen Action. Vitam Horm 1994;49:383–432. DOI: 10.1016/s0083-6729(08)61151-6.

10. Walker W.H. Non-classical actions of testosterone and spermatogenesis. Philos Trans R Soc Lond B Biol Sci 2010;365(1546):1557–69. DOI: 10.1098/rstb.2009.0258.

11. Pizzichini M., Di Stefano A., Resconi G. et al. Influence of testosterone on purine nucleotide turnover in rat kidney. Horm Metab Res 1990;22(6):334–8. DOI: 10.1055/s-2007-1004914.

12. Marinello E., Leoncini R., Terzuoli L. et al. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res 2004;36(9):614–9. DOI: 10.1055/s-2004-825923.

13. Елисеев М.С., Выходец И.Т., Круглова И.В. и др. Распространенность гиперурикемии у профессиональных спортсменов и ее роль в генезе различных патологических состояний и обменных нарушений. Современная ревматология 2018;12(3):82–8. DOI: 10.14412/1996-7012-2018-3-82-88.

14. Rosen R., Tomer Y., Carel R., Weinberger A. Serum 17-beta-estradiol and testosterone levels in asymptomatic hyperuricaemic men. Clin Rheumatol 1994;13(2):219–23. DOI: 10.1007/BF02249015.

15. Condorelli R.A., Calogero A.E., Di Mauro M. et al. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index. J Endocrinol Investig 2018;41(4):383–8. DOI: 10.1007/s40618-017-0762-3.

16. Mu L., Pan J., Yang L. et al. Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome. Reprod Biol Endocrinol 2018;16(1):104. DOI: 10.1186/s12958-018-0419-x.

17. Pui K., Waddell C., Dalbeth N. Early onset of hyperuricaemia and gout following treatment for female to male gender reassignment. Rheumatology (Oxford) 2008;47(12):1840–1. DOI: 10.1093/rheumatology/ken391.

18. Kurahashi H., Watanabe M., Sugimoto M. et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. Endocr J 2013;60(12):1321–7. DOI: 10.1507/endocrj.ej13-0203.

19. Ebert T., Jockenhövel F., Morales A., Shabsigh R. The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism with Transdermal Testosterone Gel. Eur Urol 2005;47(2):137–46. DOI: 10.1016/j.eururo.2004.09.015.

20. Sultan S., Irfan S.M., Murad S. Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera a Five Year Experience from a Tertiary Care Center. Asian Pac J Cancer Prev 2016;17(3):1531–3. DOI: 10.7314/apjcp.2016.17.3.1531.

21. Dousdampanis P., Trigka K., Fourtounas C., Bargman J.M. Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease. Ther Apher Dial 2013;18(3):220–30. DOI: 10.1111/1744-9987.12101.

22. Ghazi S., Zohdy W., Elkhiat Y., Shamloul R. Serum testosterone levels in diabetic men with and without erectile dysfunction. Andrologia 2012;44(6):373–80. DOI: 10.1111/j.1439-0272.2012.01292.x.

23. Kelly D.M., Jones T.H. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013;217(3): R25–45. DOI: 10.1530/joe-12-0455.

24. Tsai E.C., Boyko E.J., Leonetti D.L., Fujimoto W.Y. Low serum testosterone level as a predictor of increased visceral fat in JapaneseAmerican men. Int J Obes Relat Metab Disord 2000;24(4):485–91. DOI: 10.1038/sj.ijo.0801183.

25. Corona G., Mannucci E., Petrone L. et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006;18(2):190–7. DOI: 10.1038/sj.ijir.3901391.

26. Anderson P., Critchley J., Chan J. et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes 2001;25(12):1782–8. DOI: 10.1038/sj.ijo.0801837.

27. Mårin P., Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998;12(3):441–51. DOI: 10.1016/s0950-351x(98)80191-2.

28. Corona G., Mannucci E., Forti G., Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009;32(6):587–98. DOI: 10.1111/j.1365-2605.2008.00951.x.

29. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011;96(8):2341–53. DOI: 10.1210/jc.2011-0118.

30. Al Hayek A.A., Khader Y.S., Jafal S. et al. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Family Community Med 2013;20(3):179–86. DOI: 10.4103/2230-8229.122006.

31. Corona G., Giagulli V.A., Maseroli E. et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 2016;39(9):967–81. DOI: 10.1007/s40618-016-0480-2.

32. Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30(1):1–9. DOI: 10.2164/jandrol.108.006486.

33. Cao W., Zheng R.D., Xu S.H. et al. Association between Sex Hormone and Blood Uric Acid in Male Patients with Type 2 Diabetes. Int J Endocrinol 2017;2017:4375253. DOI: 10.1155/2017/4375253.

34. Lim J.H., Kim Y.K., Kim Y.S. et al. Relationship between serum uric Acid levels, metabolic syndrome, and arterial stiffness in korean. Korean Circ J 2010;40(7):314–20. DOI: 10.4070/kcj.2010.40.7.314.

35. Tong G., Hua X., Zhong Y. et al. Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients. Eur J Endocrinol 2014;170(2):237–45. DOI: 10.1530/EJE-13-0557.

36. Zharikov S., Krotova K., Hu H. et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008;295(5):C1183–90. DOI: 10.1152/ajpcell.00075.2008.

37. Kuczera P., Adamczak M., Wiecek A. Endocrine Abnormalities in Patients with Chronic Kidney Disease. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2015;36(2):109–18. DOI: 10.1515/prilozi-2015-0059.

38. Bosello O., Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000;1(1):47–56. DOI: 10.1046/j.1467-789x.2000.00008.x.

39. Christian C.A., Moenter S.M. The neurobiology of preovulatory and estradiol-induced gonadotropinreleasing hormone surges. Endocr Rev 2010;31(4):544–77. DOI: 10.1210/er.2009-0023.

40. Shiozawa A., Szabo S.M., Bolzani A. et al. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol 2017;44(3):388–96. DOI: 10.3899/jrheum.160452.

41. Mukhin I.V., Ignatenko G.A., Nikolenko V.Y. Dyshormonal disorders in gout: experimental and clinical studies. Bull Exp Biol Med 2002;133(5):491–3. DOI: 10.1023/a:1019826107916.

42. Marinello E., Riario-Sforza G., Marcolongo R. Plasma folliclestimulating hormone, luteinizing hormone, and sex hormones in patients with gout. Arthritis Rheum 1985;28(2):127–31. DOI: 10.1002/art.1780280203.

43. He Y., Yang Q., Qing Y. Altered expression of androgen and its receptor might be involved in the pathogenesis of primary gouty arthritis. Gout and Hyperuricemia 2015;2(2):56–61. DOI: 10.3966/GH1506020203.

44. Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология 2016;54(1):60–77. DOI: 10.14412/1995-4484-2016-60-77.

45. Rao P.M., Kelly D.M., Jones T.H. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol 2013;9(8):479–93. DOI: 10.1038/nrendo.2013.122.

46. Hong C.Y., Park J.H., Ahn R.S. et al. Molecular Mechanism of Suppression of Testicular Steroidogenesis by Proinflammatory Cytokine Tumor Necrosis Factor Alpha. Mol Cel Biol 2004;24(7):2593–604. DOI: 10.1128/mcb.24.7.2593-2604.

47. Hales D.B. Interleukin-1 inhibits Leydig cell steroidogenesis primarily by decreasing 17 alpha-hydroxylase/C17-20 lyase cytochrome P450 expression. Endocrinology 1992;131(5):2165–72. DOI: 10.1210/endo.131.5.1425417.

48. Vodo S., Bechi N., Petroni A. et al. Testosterone-induced effects on lipids and inflammation. Mediators Inflamm 2013;2013:183041. DOI: 10.1155/2013/183041.

49. Yang Y., Lv X., Huang W. et al. Study of androgen and atherosclerosis in old-age male. J Zhejiang Univ Sci 2005;6(9):931–5. DOI: 10.1631/jzus.2005.b0931.

50. Rettew J.A., Huet-Hudson Y.M., Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008;78(3):432–7. DOI: 10.1095/biolreprod.107.063545.

51. Coletta R.D., Reynolds M.A., MartelliJunior H. et al. Testosterone stimulates proliferation and inhibits interleukin-6 production of normal and hereditary gingival fibromatosis fibroblasts. Oral Microbiol Immunol 2002;17(3):186–92. DOI: 10.1034/j.1399-302x.2002.170309.x.

52. Corrales J.J. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 2006;189(3):595–604. DOI: 10.1677/joe.1.06779.

53. Malkin C.J., Pugh P.J., Jones R.D. et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89(7):3313–8. DOI: 10.1210/jc.2003-031069.

54. Torres-Chávez K.E., Sanfins J.M., Clemente-Napimoga J.T. et al. Effect of gonadal steroid hormones on formalininduced temporomandibular joint inflammation. Eur J Pain 2012;16(2):204–16. DOI: 10.1016/j.ejpain.2011.06.007.

55. Chen J.J., Lee S.S., Leu S.M. et al. Sex Steroids and the Induction of Human Neutrophil Cell Death by Monosodium Urate Crystals. Adaptive Medicine 2018;10(4):155–60. DOI: 10.4247/am.2018.abi218.

56. Cutolo M., Capellino S., Montagna P. et al. Sex hormone modulation of cell growth and apoptosis of the human monocytic/ macrophage cell line. Arthritis Res Ther 2005;7(5):R1124–32. DOI: 10.1186/ar1791.

57. Corcoran M.P., Meydani M., Lichtenstein A.H. et al. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol 2010;206(2):217–24. DOI: 10.1677/joe-10-0057.

58. Wang S.J., Tu H.P., Ko A.M.S. et al. Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses. J Mol Med 2011;89(12):1241–51. DOI: 10.1007/s00109-011-0796-5.

59. Zheng D., Zhao Y., Shen Y. et al. Orexin A-mediated stimulation of 3β-HSD expression and testosterone production through MAPK signaling pathways in primary rat Leydig cells. J Endocrinol Invest 2014;37(3):285–92. DOI: 10.1007/s40618-013-0035-8.

60. Гусакова Д.А., Калинченко С.Ю., Камалов А.А., Тишова Ю.А. Роль коррекции гипогонадизма в лечении и профилактике мочекаменной болезни у мужчин с метаболическим синдромом. Проблемы эндокринологии 2015;61(2):12–20. DOI: 10.14341/probl201561212-20.


Для цитирования:


Паневин Т.С. Влияние тестостерона на пуриновый обмен и подагру. Андрология и генитальная хирургия. 2021;22(3):11-17. https://doi.org/10.17650/1726-9784-2021-22-3-11-17

For citation:


Panevin T.S. Influence of testosterone on purine metabolism and gout. Andrology and Genital Surgery. 2021;22(3):11-17. (In Russ.) https://doi.org/10.17650/1726-9784-2021-22-3-11-17

Просмотров: 174


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2070-9781 (Print)
ISSN 2412-8902 (Online)

 

 

X